Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q1 2025 · 10-Q
Revenue$73.97K$73.97K+96.1% vs Q1 2024 Net Income-$1.40M-$1.40MN/M vs Q1 2024 EPS Diluted$0.00$0.00— vs Q1 2024 Gross Profit$68,331+94.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flow-$405,006N/M Free Cash Flowderived-$431,058— Margins · derivedGross margin92.4%−0.9 pt vs Q1 2024
Operating margin-472.9%+309.8 pt vs Q1 2024
Net margin-1899.2%−767.7 pt vs Q1 2024
ended Mar 31, 2025 · filed Mar 11, 2026 · 345 d after period end